8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements

Moderna ($MRNA) announced Q4 2025 financial results on Feb 13, 2026 for the quarter ended Dec 31, 2025 —…

Filed with the SEC on February 13, 2026 · Summarized by InvestorsBot

Moderna ($MRNA) announced Q4 2025 financial results on Feb 13, 2026 for the quarter ended Dec 31, 2025 — press release furnished as Exhibit 99.1. 📄📈 #earnings #Moderna

The Q4 press release (Exhibit 99.1) is furnished with the Form 8‑K — investors should review it for full revenue, ops and other metrics. $MRNA 🔎 #Q4 #biotech

The filing states the information is “furnished,” not “filed,” so it isn’t subject to Section 18 Exchange Act liabilities and isn’t automatically incorporated by reference into other filings. $MRNA ⚖️ #regulatory #investing

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from Moderna, Inc.

BREAKING: Moderna reaches settlement with Arbutus/Genevant — $950M up front, royalty-free license covering…

8-K · March 5, 2026

Moderna filed a Form 8‑K on Feb 13, 2026 furnishing a press release (Exhibit 99.1).

8-K · February 13, 2026

Moderna ($MRNA) filed an 8‑K (Item 9.01) on Feb 10, 2026 — Exhibit 99.1: press release dated Feb 10, 2026;…

8-K · February 11, 2026

FDA CBER issued a Refusal-to-File for Moderna’s BLA for investigational influenza vaccine mRNA-1010 — will…

8-K · February 11, 2026

Moderna ($MRNA) said on Feb 10, 2026 it received a Refusal-to-File letter from the FDA for its…

8-K · February 11, 2026

Moderna filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibits: 99.1 press release (dated Jan 12, 2026) and…

8-K · January 12, 2026